JP2021510723A5 - - Google Patents

Info

Publication number
JP2021510723A5
JP2021510723A5 JP2020540345A JP2020540345A JP2021510723A5 JP 2021510723 A5 JP2021510723 A5 JP 2021510723A5 JP 2020540345 A JP2020540345 A JP 2020540345A JP 2020540345 A JP2020540345 A JP 2020540345A JP 2021510723 A5 JP2021510723 A5 JP 2021510723A5
Authority
JP
Japan
Prior art keywords
powder
shell
composition according
container
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020540345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510723A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/050607 external-priority patent/WO2019145897A1/en
Publication of JP2021510723A publication Critical patent/JP2021510723A/ja
Publication of JP2021510723A5 publication Critical patent/JP2021510723A5/ja
Pending legal-status Critical Current

Links

JP2020540345A 2018-01-26 2019-01-24 吸入型治療薬の高用量送達 Pending JP2021510723A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862622464P 2018-01-26 2018-01-26
US62/622,464 2018-01-26
PCT/IB2019/050607 WO2019145897A1 (en) 2018-01-26 2019-01-24 High dose delivery of inhaled therapeutics

Publications (2)

Publication Number Publication Date
JP2021510723A JP2021510723A (ja) 2021-04-30
JP2021510723A5 true JP2021510723A5 (https=) 2022-01-19

Family

ID=65635769

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020540345A Pending JP2021510723A (ja) 2018-01-26 2019-01-24 吸入型治療薬の高用量送達

Country Status (14)

Country Link
US (1) US20210069106A1 (https=)
EP (1) EP3743045A1 (https=)
JP (1) JP2021510723A (https=)
KR (1) KR20200115560A (https=)
CN (1) CN111526870A (https=)
AR (1) AR114308A1 (https=)
AU (2) AU2019212586C1 (https=)
BR (1) BR112020014793A2 (https=)
CA (1) CA3089439A1 (https=)
CL (1) CL2020001939A1 (https=)
IL (1) IL276241A (https=)
MX (1) MX2020007745A (https=)
RU (1) RU2020127882A (https=)
WO (1) WO2019145897A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022002980A (es) 2019-09-16 2022-04-06 Amgen Inc Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
PH12022551022A1 (en) * 2019-10-28 2023-03-06 Medimmune Ltd Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
WO2026082944A1 (en) 2024-10-17 2026-04-23 Hovione Farmaciência S.A. High-density composite active particles comprising beta-lactoglobulin and api, compositions comprising same, and methods for the manufacture thereof
CN119306869B (zh) * 2024-12-13 2025-05-16 万华化学集团股份有限公司 一种乙烯/α-烯烃共聚物及其制备方法、采用其的封装胶膜

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100951750B1 (ko) 2001-11-01 2010-04-09 노바르티스 아게 분무 건조 방법 및 그 조성물
WO2004058218A2 (en) 2002-12-30 2004-07-15 Nektar Therapeutics Prefilming atomizer
KR101644250B1 (ko) * 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
JP2009544716A (ja) * 2006-07-27 2009-12-17 ノバルティス アクチエンゲゼルシャフト 肺送達のためのインスリン含有エアロゾル化可能製剤
TR200907236A2 (tr) * 2009-09-23 2011-04-21 Bi̇lgi̇ç Mahmut Tiotropyum kuru toz formülasyonunun blister ambalajda taşınması.
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
CN107596518B (zh) * 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
EP2968825A4 (en) * 2013-03-15 2016-09-07 Childrens Medical Center Gas-filled stabilized particles and methods of use
EA038332B1 (ru) * 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
KR20180050320A (ko) * 2015-09-09 2018-05-14 노파르티스 아게 분무-건조된 제제의 폐로의 표적화된 전달
CA3010446A1 (en) 2016-01-19 2017-07-27 Novartis Ag Multidose inhaler
CA3012679C (en) * 2016-01-29 2023-12-12 Mannkind Corporation Dry powder inhaler

Similar Documents

Publication Publication Date Title
AU2025204271A1 (en) Microcrystalline diketopiperazine compositions and methods
JP6491658B2 (ja) 熱安定性乾燥粉末医薬組成物及び方法
CN106163598B (zh) 尼古丁粉末吸入器
AU2019282808B2 (en) Composition and method for inhalation
US6616914B2 (en) Method for pulmonary and oral delivery of pharmaceuticals
ES2880271T3 (es) Polvos pulmonares de ultra baja densidad
JP2021510723A5 (https=)
CA2838030A1 (en) Combination comprising umeclidinium and a corticosteroid
Kaur et al. Advanced aerosol delivery devices for potential cure of acute and chronic diseases
RU2020127882A (ru) Доставка высоких доз ингаляционных терапевтических средств
US20190321290A1 (en) Composition and method for inhalation
JP2025061049A (ja) 吸入可能な乾燥粉末
Carvalho et al. Dry powder inhalation for pulmonary delivery: recent advances and continuing challenges
UA119774C2 (uk) Комбінації формотеролу і будесоніду для лікування хронічної обструктивної хвороби легень (хохл)
JP2007520507A5 (https=)
US20250228779A1 (en) Method and composition for treating pulmonary fibrosis
IT202000005026A1 (it) Lattoferrina per uso inalatorio ad azione antivirale
JP2022527054A5 (https=)
SE527200C2 (sv) Inhalatoranordning samt kombinerade doser av formaterol och fluticason
JP2023524064A (ja) ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法
EP2931252A1 (en) Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
WO2023077025A1 (en) Methods and compositions for treating pulmonary hypertension
Vecellio et al. Deposition in three nasal cast models with a new concept of nasal administration (Retronose) vs nasal spray
Hoppentocht et al. Design and development of a disposable high dose dry powder inhaler for aminoglycosides
JP6915956B2 (ja) 肺線維症の１日１回の治療